Immunotherapy plus chemo for advanced stomach cancer with fluid in belly
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination for advanced stomach cancer that has spread and caused fluid buildup in the belly (malignant ascites). It combines an immunotherapy drug (anti-PD-1) with standard chemotherapy and a targeted chemotherapy given directly into the belly to see if it can shrink the cancer and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have stomach cancer or cancer at the junction of the stomach and esophagus that has spread and cannot be removed with surgery.
- Your cancer must be HER2-negative and mismatch repair-proficient (pMMR), meaning a specific protein test shows a certain type.
- You must have moderate or more fluid buildup in the belly (ascites) and evidence that the cancer has spread to the lining of the belly.
- You must not have had prior treatment for advanced or metastatic stomach cancer; this is your first line of treatment.
- You must be willing to sign an informed consent form and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (QL1706, which is an immunotherapy, and paclitaxel, a chemotherapy drug) plus a targeted drug called bevacizumab, for people with advanced stomach cancer that has grown despite a first treatment that included immunotherapy. It aims to see if 'rechallenging' with immunotherapy in a different combination can help control the cancer.
This trial tests a combination of two drugs—one that helps your immune system fight cancer (immune checkpoint inhibitor) and one that strengthens bones (zoledronic acid)—given directly into the belly (intraperitoneal) to control fluid buildup caused by stomach cancer. It may help people with moderate to severe malignant ascites who have not had local belly treatments or immunotherapy recently.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests if adding a PD-1 immunotherapy drug to standard chemotherapy works better for advanced stomach cancer, and looks at how your gut bacteria may affect treatment. It is for people who have not had chemotherapy before and are starting their first treatment.
Hear when a new Gastric Cancer Peritoneal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.